Emirates Biotech
Emirates Biotech is a Dubai-based PLA biopolymer manufacturer, established in 2024 as a joint venture to produce and market plant-based, compostable plastics under the Embio brand. It serves packaging, food service, and industrial converters across the Middle East, Africa, and India, and is building the world's largest 160,000 tpa PLA facility in Abu Dhabi.
- Company typePrivate
- Founded2024
- HeadquartersDubai, United Arab Emirates
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Emirates Biotech does
Emirates Biotech is a Dubai-headquartered biotechnology company established in July 2024 as a joint venture between S Royal Kit Emirates Investment and Global Biopolymers Industries. The company produces and markets Polylactic Acid (PLA) biopolymers under the Embio brand as plant-based, compostable alternatives to fossil-fuel-based plastics, serving converters, brand owners, and packaging manufacturers across the Middle East, Africa, and India. Emirates Biotech describes itself as the first PLA manufacturer in the Middle East & India region and is developing the Falcon PLA Project in KEZAD, Abu Dhabi — planned as the world's largest PLA production facility at 160,000 tonnes per annum across two 80,000-tonne phases, with commissioning targeted for early 2028.
The core process technology is Sulzer's licensed PLA platform covering lactide production, purification, and polymerization — proven technology already deployed at most global PLA facilities. The Embio product portfolio comprises multiple PLA grades (EB10EX, EB20EX, EB40EX, EB10MV, EB20MV, EB10HF) for rigid and flexible packaging, coated paper board, fibers, nonwovens, and 3D printing, with verified compliance to food-contact, bio-based, and compostability standards. Beyond commercial PLA, Emirates Biotech manages the polymerisation stage in the EU-funded CIRCLE consortium (€27 million, Horizon Europe, 17 partners) to convert lactic acid from food waste into high-purity PLA for automotive, cosmetics, and food packaging, and runs research partnerships with UAEU and Heriot-Watt University.
Emirates Biotech operates a B2B direct-sales model through regional Sales Development Managers covering the UAE, Oman, India, KSA, Bahrain, and Kuwait, supplemented by participation in industry trade shows (ArabPlast, Saudi Plastics & Petrochem, European Bioplastics Conference, PolyNext, Plastics Recycling Show). Embio products are distributed from local UAE inventory with smaller minimum order volumes to support regional converters and brand owners. The company is pre-revenue on the production side — the Embio range was launched in November 2025 and is in pre-marketing, while world-scale manufacturing remains under construction. Financial commitments to the Falcon PLA Project exceed USD 90 million, anchored by an equipment supply contract with Sulzer and an EPC contract with SAMSUNG E&A.
Emirates Biotech firmographics
Firmographics- Name
- Emirates Biotech
- Legal name
- EMIRATES BIOTECH INDUSTRIES LTD
- Website
- https://emiratesbiotech.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Emirates Biotech is a Dubai-based PLA biopolymer manufacturer, established in 2024 as a joint venture to produce and market plant-based, compostable plastics under the Embio brand. It serves packaging, food service, and industrial converters across the Middle East, Africa, and India, and is building the world's largest 160,000 tpa PLA facility in Abu Dhabi.
- Ownership category
- akta.pro rank
Emirates Biotech industry classification
Industry- Product category
- PLA Biopolymers / Bioplastics Manufacturing
- NAICS
- Resin, Synthetic Rubber, and Artificial and Synthetic Fibers and Filaments Manufacturing (3252), Plastics Packaging Film and Sheet (including Laminated) Manufacturing (326112)
- SIC
- Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)
- akta.pro primary industry
- Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends) (IMANAAAG)
- akta.pro secondary industries
- Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT) (IMAEAOAA), Compostable & Bio-Based Packaging (PLA/PHA, Starch Blends, Cellulose Films) (IMALAMAB), Compostable & Bio-Based Flexible Packaging (PLA, PHA, Cellulose Films) (IMALABAO)
Keywords
Where Emirates Biotech is headquartered
LocationHeadquarters
- HQ city
- Dubai
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices3 records
Markets served
Emirates Biotech business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D, Marketing or Sales
Revenue model
- PLA Biopolymer Sales: Direct sales of Embio PLA biopolymers to regional converters, brand owners, and packaging manufacturers across the Middle East. Products sold with local UAE inventory for faster delivery and smaller minimum order volumes.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels4 records
Emirates Biotech product offering
Product offeringCore offering
Emirates Biotech manufactures and sells Polylactic Acid (PLA) biopolymers under the Embio brand, marketed as plant-based, recyclable, and compostable alternatives to fossil-based plastics for rigid and flexible packaging, coated paper board, fibers, nonwovens, and 3D printing applications. Products are sold in multiple grades (EB10EX, EB20EX, EB40EX, EB10MV, EB20MV, EB10HF) with verified compliance to food-contact, bio-based, and compostability standards, and stocked locally in the UAE for regional converters, brand owners, and packaging manufacturers.
Product overview
Emirates Biotech offers a portfolio of PolyLactic Acid (PLA) biopolymers under the Embio brand, including grades EB10EX, EB20EX, EB40EX, EB10MV, EB20MV, and EB10HF for applications including rigid and flexible packaging, coated paper board, fibers, nonwovens, and 3D printing. The company's manufacturing capabilities are anchored by the Falcon PLA Project, an upcoming 160,000 tonnes per annum facility in Abu Dhabi that will be the world's largest PLA production plant when operational in 2028. Emirates Biotech also participates in the CIRCLE consortium, a European research initiative to produce PLA from food waste, demonstrating commitment to circular economy principles.
Differentiator
Problem solved
Functional benefit
Brands
- Embio: Product range of PolyLactic Acid (PLA) biopolymers designed as sustainable alternatives to traditional plastics. Includes grades for rigid and flexible packaging, coated paper board, fibers, nonwovens, and 3D printing. Launched in November 2025.
Products and services
- Embio PLA Biopolymers A line of PolyLactic Acid (PLA) biopolymers marketed under the Embio brand, offering plant-based, recyclable, and industrially compostable alternatives to fossil-based plastics. The portfolio includes grades EB10EX, EB20EX, EB40EX, EB10MV, EB20MV, and EB10HF designed for rigid and flexible packaging, coated paper board, fibers, nonwovens, and 3D printing applications, with verified compliance to food-contact, bio-based, and compostability standards. Products are stocked locally in the UAE for regional converters, brand owners, and packaging manufacturers.
Quantifiable outcome
- 160,000 tonnes per annum PLA production capacity - enough to replace approximately 3.2 billion plastic bottles
- +2 more outcomes
Companies that use Emirates Biotech
Customer profileSegments8 records
Ideal customer profiles2 records
Emirates Biotech technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Emirates Biotech partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered flagship, minor and core.
- CIRCLE ConsortiumflagshipFour-year European research project funded by Horizon Europe with €27 million funding and 17 partners across the value chain. Emirates Biotech manages polymerization of lactic acid derived from food waste into high-purity PLA. Consortium includes partners such as Volkswagen, FrieslandCampina, Davines, Sulzer and Sulapac.
- Heriot-Watt UniversityminorCollaboration on HQ design competition with 17 student teams submitting proposals. Heriot-Watt University received runner-up recognition for structural framework design.
- United Arab Emirates University (UAEU)coreStrategic partnership for collaborative research on novel PLA applications and end-of-life solutions. Engages UAEU's students and faculty, leveraging university facilities to optimize PLA performance and environmental benefits.
- SAMSUNG E&AcoreSAMSUNG E&A selected as contractor for Falcon PLA Project, overseeing all engineering, procurement, and construction work. Pre-EPC contract signed April 2025. Company has unrivalled track record in delivering complex industrial projects.
- SulzercoreSulzer selected as technology provider for PLA production facility using their licensed PLA technology covering lactide production, purification and polymerization. Equipment supply contract signed in May 2025. Sulzer's technology is already in use at most PLA facilities worldwide.
- PESCOminorProject management consultant for Falcon PLA Project development and execution.
- KEZADcoreKEZAD (Khalifa Economic Zones Abu Dhabi) serves as the hosting free zone for the Falcon PLA production facility in Abu Dhabi, providing infrastructure and services.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
Emirates Biotech competitors and assessment
Company assessmentEmerging players
- RWDC Industries: Producer of PHA biopolymers (Solon) for food service ware, packaging, and coatings. Emerging alternative to PLA in compostable plastics end-markets targeted by Emirates Biotech.
- Danimer Scientific: US-based producer of PHA biopolymers (Nodax) for compostable packaging, food service, and coatings. Competes with PLA in the same bioplastics substitution thesis and overlapping end-markets.
- Novamont: Italian bioplastics producer (Mater-Bi starch-based and biopolyesters) competing in compostable packaging and food service ware. Adjacent technology platform but directly competes with PLA in compostable single-use applications.
Direct peers
- NatureWorks: Global leader in PLA biopolymers (Ingeo brand) and former employer of Emirates Biotech's CEO and CTO. Most directly comparable PLA producer with established grades, global customers, and world-scale manufacturing capacity.
- Futerro: Belgian PLA producer with integrated lactic acid to PLA technology. Competes in the same PLA biopolymer category as Emirates Biotech, supplying converters and brand owners across packaging and durable applications.
- TotalEnergies Corbion: Joint venture between TotalEnergies and Corbion producing Luminy PLA biopolymers. Direct global PLA competitor and former employer of Emirates Biotech's CCO; operates world-scale PLA capacity in Thailand.
- TianAn Biopolymer (Sinopec subsidiary): One of China's largest PLA producers with multi-tens-of-thousands of tonnes capacity under the Sulzer license. Competes directly with Emirates Biotech in commodity PLA supply to converters, particularly across Asia and export markets.
Others
- Sulzer: Swiss industrial engineering and licensing company supplying the proprietary PLA process technology to Emirates Biotech. Both a core technology partner and a key enabler (and indirect beneficiary) of Emirates Biotech's 160,000 tpa Falcon facility.
Regional players
- Unitika: Japanese manufacturer of PLA fibers, films, and nonwovens under the Terramac brand. Comparable PLA-based product portfolio serving packaging and fiber markets, but focused primarily on the Japanese and Asian markets rather than MEAI.
Broad incumbents
- BASF (ecovio / bioplastics): Diversified chemicals giant producing ecovio compostable bioplastics (blends including PLA). Overlaps with Emirates Biotech in compostable packaging and agricultural film end-markets, but PLA is one product line within a much broader chemicals portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Emirates Biotech social profiles
Digital presenceEmirates Biotech compliance and trust
Trust signalCompliance3 records
Emirates Biotech financial estimates
Financial estimateRevenue estimate
Valuation estimate
Emirates Biotech leadership team
Management profileNumber of profiles
Profiles6 records
Emirates Biotech funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Emirates Biotech M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Emirates Biotech
What does Emirates Biotech do?
Emirates Biotech manufactures and sells Polylactic Acid (PLA) biopolymers under the Embio brand, marketed as plant-based, recyclable, and compostable alternatives to fossil-based plastics for rigid and flexible packaging, coated paper board, fibers, nonwovens, and 3D printing applications. Products are sold in multiple grades (EB10EX, EB20EX, EB40EX, EB10MV, EB20MV, EB10HF) with verified compliance to food-contact, bio-based, and compostability standards, and stocked locally in the UAE for regional converters, brand owners, and packaging manufacturers.
Is Emirates Biotech a public or private company?
Emirates Biotech is a private company. It is classified as corporate owned and is currently operating.
When was Emirates Biotech founded?
Emirates Biotech was founded in 2024. It employs 101 to 250 people.
Where is Emirates Biotech based?
Emirates Biotech is headquartered in Dubai, United Arab Emirates, in the Middle East region.
How does Emirates Biotech make money?
One revenue line is on record: PLA Biopolymer Sales.
Who are Emirates Biotech's main competitors?
Emerging players on record are RWDC Industries, Danimer Scientific and Novamont. Direct peers are NatureWorks, Futerro, TotalEnergies Corbion and TianAn Biopolymer (Sinopec subsidiary). Sulzer is listed as an others. Unitika is listed as a regional player. BASF (ecovio / bioplastics) is listed as a broad incumbent.
Does Emirates Biotech have an API?
No public API is recorded for Emirates Biotech.
What industry is Emirates Biotech in?
Emirates Biotech's product category is PLA Biopolymers / Bioplastics Manufacturing. Its primary akta.pro industry code is IMANAAAG, Bio-based & Biodegradable Polymer Resin Manufacturing (PLA, PHA, PBS, starch blends), with a secondary code of IMAEAOAA, Biodegradable Polymers & Resins (PLA, PHA, PBS, PBAT). Its NAICS code is 3252 and its SIC code is 2821.